Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.
J Clin Lab Anal. 2015 Nov ;29(6):480-4. Epub 2014 Sep 23. PMID: 25252033
BACKGROUND: The prevalence of non-B or non-C hepatocellular carcinoma (NBNC-HCC) has been increasing all over the world. Advanced glycation end products (AGE) play a role in the pathogenesis of alcoholic liver injury or nonalcoholic steatohepatitis (NASH).
METHODS: We examined here whether serum levels of AGE were elevated in NBNC-HCC patients compared with NASH subjects without HCC and investigated which anthropometric and clinical variables were independent determinants of AGE.
RESULTS: Ninety NBNC-HCC, 56 NASH, and 27 control subjects underwent a complete history and physical examination, determination of blood chemistries, including AGE levels. Serum levels of AGE were significantly higher in NBNC-HCC patients compared with NASH and control subjects [9.1± 2.7, 5.2 ± 1.7, 3.5 ± 1.2 (U/ml), respectively, P<0.05]. Univariate analysis showed that AGE levels were associated with male (P<0.05), age (P<0.01), aspartate aminotransferase (P<0.05),γ-glutamyl transpeptidase (GGT) (P<0.01), HDL-cholesterol (inversely, P<0.01), fasting plasma glucose (P<0.01), and HbA1c (P<0.05). By the use of multiple stepwise regression analysis, age, GGT, and HDL-cholesterol (inversely) remained significant and were independently related to AGE levels (R(2) = 0.406).
CONCLUSION: The present results suggest that AGE might be involved in the pathogenesis of NBNC-HCC, thereby being a biomarker that could discriminate NBNC-HCC from NASH.